Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Peijia Medical Ltd. ( (HK:9996) ).
Peijia Medical Ltd. has announced that its registration application for the TaurusTrio Transcatheter Aortic Valve System has been accepted by the National Medical Products Administration of China. This system, developed under an exclusive license from JenaValve Technology, is intended for patients with severe aortic regurgitation and will benefit from priority review under the NMPA’s Special Review and Approval Procedure for Innovative Medical Devices, potentially enhancing the company’s market position.
More about Peijia Medical Ltd.
Peijia Medical Ltd. is a company in the medical device industry, focusing on developing and manufacturing innovative medical solutions. Their primary products include transcatheter aortic valve systems, which are designed to treat severe aortic regurgitation.
YTD Price Performance: 2.52%
Technical Sentiment Signal: Buy
Current Market Cap: €343M
See more data about 9996 stock on TipRanks’ Stock Analysis page.